Biosimilar agents in oncology/haematology: from approval to practice
2011
Biosimilar Agents in Oncology and Haematology
publication
Evidence: moderate
Author Information
Author(s): Dietger Niederwieser, Stephan Schmitz
Primary Institution: Universitätsklinikum Leipzig
Conclusion
Biosimilars are increasingly being approved for use in oncology, but their regulation and clinical application are still evolving.
Supporting Evidence
- Biosimilars are not identical copies of biologics due to their complex manufacturing processes.
- The European Medicines Agency has established guidelines for the approval of biosimilars.
- Biosimilars are used in oncology to support patients undergoing chemotherapy.
Takeaway
Biosimilars are medicines that are similar to existing biologics but not identical, and they are now being used in cancer treatment.
Methodology
This review discusses the regulatory framework, approval processes, and clinical implications of biosimilars in oncology.
Potential Biases
Potential bias may arise from the authors' affiliations with pharmaceutical companies.
Limitations
The review does not provide specific clinical trial data or outcomes for the biosimilars discussed.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website